Retatrutide (LY-3437943) is an investigational peptide developed by Eli Lilly that simultaneously activates three metabolic hormone receptors: GLP-1, GIP, and glucagon. In Phase 2 clinical trials, it produced the highest weight loss ever recorded in an obesity medication trial — 24.2% mean body weight reduction at 48 weeks. For context, that approaches the lower end of bariatric surgery outcomes. The drug is not yet FDA approved, but the Phase 3 TRIUMPH program is actively enrolling across dozens of countries, with data readouts expected in 2026 and a potential FDA submission thereafter.
This article reviews the published clinical data, the real-world experiences of trial participants, the mechanism that differentiates retatrutide from semaglutide and tirzepatide, and the practical questions patients are asking while they wait for approval.
The mechanism: why three receptors matter
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates GLP-1 and GIP. Retatrutide adds glucagon receptor activation to create a triple agonist. Each receptor contributes a distinct metabolic effect.
GLP-1 receptor agonism suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the foundation of all current GLP-1 obesity medications. GIP receptor agonism adds insulin secretion enhancement and appears to improve adipose tissue metabolism, possibly explaining why tirzepatide outperforms semaglutide despite both having strong GLP-1 activity.
The glucagon receptor is the novel component. Glucagon is traditionally viewed as a counter-regulatory hormone that raises blood glucose, but it also increases resting energy expenditure, promotes hepatic fat oxidation, and stimulates ketogenesis. In retatrutide, the glucagon activity is balanced against the glucose-lowering effects of GLP-1 and GIP, so net glycemic control still improves dramatically. The energy expenditure effect may explain why retatrutide's weight loss continues to accelerate between weeks 24 and 48 rather than plateauing, which is unusual for GLP-1 monotherapy.
Phase 2 obesity data: the 24.2% result
The landmark Phase 2 trial was published in the New England Journal of Medicine in 2023 (PMID: 37366315). It enrolled 338 adults with obesity or overweight without diabetes. Participants were randomized to placebo or retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg, administered subcutaneously once weekly for 48 weeks.
The results were dose-dependent and striking. At 12 mg, mean weight loss was 24.2% at 48 weeks. At 8 mg, it was 21.1%. Even the 4 mg dose achieved 14.2%. Some individual participants lost more than 30% of their body weight. For comparison, the average gastric bypass patient loses 25–35% of body weight. The 24.2% figure moved the conversation from 'medication versus lifestyle' to 'medication versus surgery.'
What was equally notable was the durability trajectory. Weight loss was still increasing at week 48, not plateauing. This suggests the maximum effect had not yet been reached. Phase 3 trials, which run 72–89 weeks, will clarify where the curve flattens.
Phase 2 diabetes data and body composition
A parallel Phase 2 trial in adults with type 2 diabetes was published in The Lancet (PMID: 37385280). At the 12 mg dose, retatrutide reduced HbA1c by 2.16% and body weight by 16.94%. These are among the largest glycemic improvements ever reported in a diabetes pharmacotherapy trial.
A substudy using DEXA scans assessed body composition (PMID: 40609566). The finding was clinically meaningful: approximately 85% of the weight lost was fat mass, and 15% was lean mass. Diet-induced weight loss typically produces a 70/30 or 60/40 fat-to-lean ratio. The favorable composition on retatrutide may reflect the glucagon-mediated increase in energy expenditure, which preferentially mobilizes adipose tissue over muscle.
However, this does not mean muscle preservation is automatic. Participants in the diabetes trial were not specifically counseled on resistance training. The lean mass preservation was a pharmacological effect, but exercise and adequate protein intake remain essential for anyone using retatrutide or any weight-loss medication.
The Phase 3 TRIUMPH program
Eli Lilly launched the TRIUMPH program in 2023, a series of Phase 3 trials designed to support FDA approval across multiple indications. The key trials include:
- TRIUMPH-1: Obesity and overweight, including subsets with knee osteoarthritis and obstructive sleep apnea (NCT05929066)
- TRIUMPH-2: Type 2 diabetes (TRANSCEND program; multiple trials including head-to-head vs. semaglutide)
- TRIUMPH-3: Obesity with established cardiovascular disease (NCT05882045)
- TRIUMPH-5: Head-to-head versus tirzepatide in obesity — no placebo arm (NCT06662383)
- TRIUMPH-OUTCOMES: 5-year cardiovascular and renal outcomes trial in 10,000 participants (NCT06383390)
What trial participants are reporting
The r/RetatrutideTrial community on Reddit has become an informal registry of participant experiences. While uncontrolled and self-reported, these narratives provide texture that clinical trial publications cannot capture.
A participant in TRIUMPH-3 reported losing 27% of body weight at 30 weeks, with BMI dropping from 36.2 to 26.4. Their HbA1c fell from 6.7% to 5.4%, and they were able to stop one blood pressure medication and reduce two others. A DEXA scan showed 85% fat loss and 15% lean loss.
Another participant in the TRIUMPH-5 head-to-head trial described profound appetite suppression: 'I literally forget to eat. I can walk past a bakery and feel nothing.' They also noted an unexpected side effect — skin sensitivity (allodynia) on the arms and legs, rated 2–3 out of 10, which flared with each dose increase. This symptom is not prominently featured in published trial data but has been reported by multiple participants.
Some participants have used continuous glucose monitors and urine ketone strips to distinguish whether they are on retatrutide or tirzepatide in the blinded TRIUMPH-5 trial. Trace ketones (0.5 mmol/L) after carbohydrate-rich meals suggest glucagon-driven fat oxidation, a signature of retatrutide's triple mechanism.
Side effects: what to expect
The side effect profile of retatrutide is consistent with the GLP-1 drug class. Gastrointestinal symptoms dominate, are dose-dependent, and are most pronounced during dose escalation. In the Phase 2 obesity trial, nausea, vomiting, diarrhea, and constipation were the most common adverse events. Discontinuation due to side effects was relatively low.
- Nausea: most common; peaks during dose increases, usually resolves within days
- Diarrhea and vomiting: typically transient, managed with hydration and dietary adjustments
- Constipation: may persist longer than other GI effects; fiber and fluid intake help
- Fatigue and headache: less common, usually mild
- Skin sensitivity/allodynia: reported anecdotally by trial participants; not well-characterized in literature
- Mild heart rate increase: observed in some participants
How retatrutide compares to available options
For patients considering whether to wait for retatrutide or start tirzepatide or semaglutide now, the decision depends on clinical urgency, insurance coverage, and personal preference.
Tirzepatide (Zepbound) is already available and produces up to 22.5% weight loss — only modestly less than retatrutide's Phase 2 results. Semaglutide (Wegovy) produces ~15% weight loss but has the strongest cardiovascular outcome data (SELECT trial). Both are established, reimbursed for many patients, and have well-characterized safety profiles.
Retatrutide's advantages, if Phase 3 confirms Phase 2, will be: slightly greater weight loss, potentially better liver fat reduction due to glucagon activity, and the energy expenditure effect that may reduce plateauing. Its disadvantages are: no long-term safety data yet, no cardiovascular outcome data yet, no guarantee of approval timeline, and unknown pricing and insurance coverage at launch.
The clinical consensus is clear: if you have obesity or type 2 diabetes today, do not wait. Start an available agent. The metabolic benefits of treating now outweigh the theoretical benefits of a slightly more effective drug that may not be available for 1–2 years.
Sourcing and regulatory reality
Retatrutide is not available by prescription. It is not legal to sell in the United States, European Union, or other major markets. Products labeled as 'research-grade retatrutide' from online peptide vendors are unregulated. The FDA has issued warning letters to companies selling research-labeled semaglutide, tirzepatide, and retatrutide. These products carry risks of underdosing, contamination, and outright fraud.
The only legitimate way to access retatrutide before approval is through a clinical trial. Trials are recruiting globally through the TRIUMPH and TRANSCEND programs. Most require a 90-day washout from all other weight-loss medications and a stable weight history. For eligible participants, trials provide free medication, medical monitoring, and the opportunity to contribute to scientific evidence.
The bottom line
Retatrutide represents the next evolution in incretin-based pharmacotherapy. Its triple-receptor mechanism, unprecedented Phase 2 weight loss, and favorable body composition data make it the most promising obesity drug in development. But promise is not proof. Phase 3 data will determine whether the 24.2% figure holds in larger, more diverse populations, whether rare adverse events emerge, and whether the cardiovascular and renal outcome trials confirm benefit beyond weight loss.
For now, retatrutide is a drug to watch, not a drug to buy. Patients with obesity should not delay treatment waiting for it. Clinicians should monitor the TRIUMPH readouts. And anyone considering unregulated online sourcing should understand that the risks — clinical, legal, and financial — far outweigh any potential benefit.